This is the authors' abstract. We don't add key points for this paper.
The World Health Organization has recently updated their dosing schedule recommendations for the human papillomavirus (HPV) vaccine to include a single-dose schedule. We review the biologic plausibility of a single dose, the evidence from clinical trials, post-licensure observational studies, and mathematical modeling for a single-dose schedule. We also discuss the implications of countries switching to a single-dose program from a two or three-dose schedule. Finally, we review the countries that have currently switched to or introduced the vaccine with a single-dose schedule.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Stanley et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: